Australia markets closed

Purple Biotech Ltd (PPBT.TA)

Tel Aviv - Tel Aviv Delayed price. Currency in ILA (0.01 ILS)
Add to watchlist
16.80-1.70 (-9.19%)
As of 03:28PM IDT. Market open.
Currency in ILA

Valuation measures4

Market cap (intra-day) 52.31M
Enterprise value 12.78M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)0.45
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 0.49
52-week change 3-65.42%
S&P500 52-week change 322.55%
52-week high 367.00
52-week low 316.80
50-day moving average 321.40
200-day moving average 331.43

Share statistics

Avg vol (3-month) 3343.94k
Avg vol (10-day) 3306.75k
Shares outstanding 5282.76M
Implied shares outstanding 6296.52M
Float 823.6M
% held by insiders 10.38%
% held by institutions 10.00%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 430 Oct 2012
Last split factor 21:20
Last split date 306 Jan 2019

Financial highlights

Currency in USD.

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-29.07%
Return on equity (ttm)-48.26%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -21.57M
Net income avi to common (ttm)-18.76M
Diluted EPS (ttm)-0.30
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)10.85M
Total cash per share (mrq)0.4
Total debt (mrq)307k
Total debt/equity (mrq)0.99%
Current ratio (mrq)1.34
Book value per share (mrq)1.14

Cash flow statement

Operating cash flow (ttm)-18.94M
Levered free cash flow (ttm)-8.28M